A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

NCT06672263 · clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
120
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.